Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | Sigma A6730 | 3.0 | uM | 3 | IFN-a2 | 43.5 | 56 | ||||
RA2159 | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 37.5 | 66 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 44.0 | 80 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 53.0 | 93 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 52.0 | 67 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 44.0 | 65 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 26.0 | 70 | |
RA2159 | PI103 | 0.1 | uM | 3 | IFN-a2 | 20.0 | 59 | ||||
N2586 | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 120.0 | 50 | ||||
N2586 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 170.5 | 72 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 162.0 | 55 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 187.5 | 58 | |
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 49.5 | 46 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 56.5 | 74 | |
N2586 | PI103 | 0.1 | uM | 3 | IFN-a2 | 31.0 | 56 | ||||
0 | IFN-a2 | 16.0 | 50 | ||||||||
RA2159 | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 82.5 | 56 | ||||
RA2159 | PD184352 | 0.1 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 71.0 | 61 | |
RA2159 | Lestaurtinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 73.0 | 72 | |
RA2159 | Ruxolitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 67.0 | 47 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 65.5 | 58 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 39.0 | 67 | |
RA2159 | EO1428 | 1.0 | uM | 3 | IFN-a2 | 21.0 | 27 | ||||
N2586 | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 156.0 | 68 | ||||
N2586 | PD184352 | 0.1 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 163.5 | 66 |